Login
$TGTX
$62.74 -$0.02 (0.03%) After hours

$TGTX SEC Filings

Filed On Filing
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million

27 Oct 2026 SCHEDULE 13G/A
14 Sep 2026 Form 4: Charney Laurence N, Director

Sold 5,000 shares ($275K)

10 Sep 2026 144
07 Aug 2026 Form 4: Charney Laurence N, Director

Gave 5,100 shares as a gift · Gave 950 shares as a gift

05 Aug 2026 FORM 10-Q
03 Aug 2026 8-K: Results of Operations and Financial Condition

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million

15 Jun 2026 Form 4: Lonial Sagar, Director

Granted 8,325 Stock Tracking Unit

15 Jun 2026 Form 4: Hume Daniel, Director

Granted 8,325 Stock Tracking Unit

15 Jun 2026 Form 4: Hoberman Kenneth, Director

Granted 8,325 Stock Tracking Unit

15 Jun 2026 Form 4: Echelard Yann, Director

Granted 8,325 Stock Tracking Unit

15 Jun 2026 Form 4: Charney Laurence N, Director

Granted 8,325 Stock Tracking Unit

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On Thursday, June 11, 2026, at 9:30 a.m. Eastern Time, by means of an online meeting platform, TG Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting. Stockholders representing 113,003,414, or 73.81%, of the 153,093,879 outst...

03 Jun 2026 8-K: Other Events

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027

27 May 2026 8-K: Other Events

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only

06 May 2026 FORM 10-Q
06 May 2026 8-K: Results of Operations and Financial Condition

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million

30 Apr 2026 Proxy statement: annual meeting on June 11, 2026

CEO pay $25.6M, up 36% · say-on-pay vote

29 Apr 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support